Analysis of imatinib in bone marrow and plasma samples of chronic myeloid leukaemia patients using solid phase extraction LC-ESI-MS

Zafar Iqbal, Moira Elliott, David Watson, Tessa Holyoake, Heather Jørgensen

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The LC-ESI-MS was developed and validated for the analysis of imatinib in plasma and bone marrow samples using deuterated imatinib (D(8)-IM) as an internal standard. The biological samples were extracted using Strata-X-C SPE cartridges and separated on C(8) column (50 x 3 mm, 3 μm), and methanol: 0.1% formic acid (70:30) was delivered at the rate of 0.7 ml/min as a mobile phase. Imatinib was quantified in samples by monitoring the ions m/z 494.3 for imatinib and 502.3 for D(8)-imatinib on mass spectrometer. The method was linear in the concentration range of 1-1500 ng/250 μl in spiked human plasma samples and limit of quantification was 5 ng/mL. Inter-day and intra-day variations in spiked human plasma spiked with 50, 250 and 500 ng /mL were less than 3.16%. The repeatability and reproducibility and other parameters of the methods were also validated. The method was employed for the analysis of the imatinib in human plasma and bone marrow samples. The drug levels in bone marrow and plasma samples were correlated to the degree of cytogenetic response. No significant difference of imatinib level between blood and bone marrow in IM-treated patients dosed to steady state was observed.
LanguageEnglish
Pages285-291
Number of pages7
JournalPakistan journal of pharmaceutical sciences
Volume24
Issue number3
Publication statusPublished - 2011

Fingerprint

Solid Phase Extraction
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bone Marrow
formic acid
Imatinib Mesylate
Cytogenetics
Methanol
Ions
Pharmaceutical Preparations

Keywords

  • bone marrow
  • plasma
  • chronic myeloid leukaemia
  • leukaemia

Cite this

@article{a0864efb638043d98ad24799adbbe91a,
title = "Analysis of imatinib in bone marrow and plasma samples of chronic myeloid leukaemia patients using solid phase extraction LC-ESI-MS",
abstract = "The LC-ESI-MS was developed and validated for the analysis of imatinib in plasma and bone marrow samples using deuterated imatinib (D(8)-IM) as an internal standard. The biological samples were extracted using Strata-X-C SPE cartridges and separated on C(8) column (50 x 3 mm, 3 μm), and methanol: 0.1{\%} formic acid (70:30) was delivered at the rate of 0.7 ml/min as a mobile phase. Imatinib was quantified in samples by monitoring the ions m/z 494.3 for imatinib and 502.3 for D(8)-imatinib on mass spectrometer. The method was linear in the concentration range of 1-1500 ng/250 μl in spiked human plasma samples and limit of quantification was 5 ng/mL. Inter-day and intra-day variations in spiked human plasma spiked with 50, 250 and 500 ng /mL were less than 3.16{\%}. The repeatability and reproducibility and other parameters of the methods were also validated. The method was employed for the analysis of the imatinib in human plasma and bone marrow samples. The drug levels in bone marrow and plasma samples were correlated to the degree of cytogenetic response. No significant difference of imatinib level between blood and bone marrow in IM-treated patients dosed to steady state was observed.",
keywords = "bone marrow, plasma, chronic myeloid leukaemia, leukaemia",
author = "Zafar Iqbal and Moira Elliott and David Watson and Tessa Holyoake and Heather J{\o}rgensen",
year = "2011",
language = "English",
volume = "24",
pages = "285--291",
journal = "Pakistan journal of pharmaceutical sciences",
issn = "1011-601X",
publisher = "Pakistan Journal of Pharmaceutical Sciences",
number = "3",

}

Analysis of imatinib in bone marrow and plasma samples of chronic myeloid leukaemia patients using solid phase extraction LC-ESI-MS. / Iqbal, Zafar; Elliott, Moira; Watson, David; Holyoake, Tessa; Jørgensen, Heather.

In: Pakistan journal of pharmaceutical sciences, Vol. 24, No. 3, 2011, p. 285-291.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Analysis of imatinib in bone marrow and plasma samples of chronic myeloid leukaemia patients using solid phase extraction LC-ESI-MS

AU - Iqbal, Zafar

AU - Elliott, Moira

AU - Watson, David

AU - Holyoake, Tessa

AU - Jørgensen, Heather

PY - 2011

Y1 - 2011

N2 - The LC-ESI-MS was developed and validated for the analysis of imatinib in plasma and bone marrow samples using deuterated imatinib (D(8)-IM) as an internal standard. The biological samples were extracted using Strata-X-C SPE cartridges and separated on C(8) column (50 x 3 mm, 3 μm), and methanol: 0.1% formic acid (70:30) was delivered at the rate of 0.7 ml/min as a mobile phase. Imatinib was quantified in samples by monitoring the ions m/z 494.3 for imatinib and 502.3 for D(8)-imatinib on mass spectrometer. The method was linear in the concentration range of 1-1500 ng/250 μl in spiked human plasma samples and limit of quantification was 5 ng/mL. Inter-day and intra-day variations in spiked human plasma spiked with 50, 250 and 500 ng /mL were less than 3.16%. The repeatability and reproducibility and other parameters of the methods were also validated. The method was employed for the analysis of the imatinib in human plasma and bone marrow samples. The drug levels in bone marrow and plasma samples were correlated to the degree of cytogenetic response. No significant difference of imatinib level between blood and bone marrow in IM-treated patients dosed to steady state was observed.

AB - The LC-ESI-MS was developed and validated for the analysis of imatinib in plasma and bone marrow samples using deuterated imatinib (D(8)-IM) as an internal standard. The biological samples were extracted using Strata-X-C SPE cartridges and separated on C(8) column (50 x 3 mm, 3 μm), and methanol: 0.1% formic acid (70:30) was delivered at the rate of 0.7 ml/min as a mobile phase. Imatinib was quantified in samples by monitoring the ions m/z 494.3 for imatinib and 502.3 for D(8)-imatinib on mass spectrometer. The method was linear in the concentration range of 1-1500 ng/250 μl in spiked human plasma samples and limit of quantification was 5 ng/mL. Inter-day and intra-day variations in spiked human plasma spiked with 50, 250 and 500 ng /mL were less than 3.16%. The repeatability and reproducibility and other parameters of the methods were also validated. The method was employed for the analysis of the imatinib in human plasma and bone marrow samples. The drug levels in bone marrow and plasma samples were correlated to the degree of cytogenetic response. No significant difference of imatinib level between blood and bone marrow in IM-treated patients dosed to steady state was observed.

KW - bone marrow

KW - plasma

KW - chronic myeloid leukaemia

KW - leukaemia

UR - http://www.pjps.pk/anon_ftp/Paper-7.pdf

M3 - Article

VL - 24

SP - 285

EP - 291

JO - Pakistan journal of pharmaceutical sciences

T2 - Pakistan journal of pharmaceutical sciences

JF - Pakistan journal of pharmaceutical sciences

SN - 1011-601X

IS - 3

ER -